Syndicate content

BROCA Panel Provides Comprehensive Testing of All Known Breast Cancer Genes

Since 1994, many thousands of women with breast cancer from families severely affected with the disease have been tested for inherited mutations in BRCA1 and BRCA2 by the Myriad Genetics test. The vast majority of those patients were told that their gene sequences were normal. With the development of modern genomics sequencing tools, the discovery of additional genes implicated in breast cancer, and the change in the legal status of genetic testing for BRCA1 and BRCA2 due to the June 13, 2013 U.S. Supreme Court decision to bar the patenting of naturally occurring genes that ended Myriad’s monopoly on the testing for BRCA1 and BRCA2 mutations, it is now possible to determine how often families in these circumstances actually do carry cancer-predisposing mutations in BRCA1, BRCA2, or any of a number of breast cancer-associated genes, despite the results of their previous genetic tests. This was the challenge addressed by Mary-Claire King (photo), Ph.D., American Cancer Society Professor of Medicine and Genome Sciences at the University of Washington, Seattle, past President of the ASHG, and renowned breast cancer genetic researcher; and Tomas Walsh, Ph.D., Associate Research Professor of Medical Genetics, also at the University of Washington, Seattle. The researchers conducted complete genomic sequencing of all genes known to be implicated in breast cancer on DNA samples from breast cancer patients who had normal BRCA1 and BRCA2 commercial test results (Myriad testing). The commercial testing occurred because the patients had a severe family history of breast cancer, defined as a family with three or more relatives affected by breast or ovarian cancer. The results were presented today by Dr. Walsh at the American Society of Human Genetics 2013 annual meeting in Boston. The researchers found that over 25 percent of index patients with normal results from commercial testing of BRCA1 and BRCA2, but with families severely affected by breast cancer, could be resolved (i.e., the breast cancer-associated gene could be identified) by sequencing all genes known to be involved in breast cancer. Sequencing was carried out using BROCA, an openly available (that is, unpatented), targeted capture and genomic sequencing approach that was developed and validated by Drs. Walsh and King in 2010. The BROCA panel was named for Dr. Paul Broca, the renowned French physician best known for his work on Broca’s area of the brain, which is responsible for articulated language. The BROCA panel detects all single-base substitutions, insertions and deletions, and copy number variants in all 24 genes known to be implicated in breast cancer. The researchers used BROCA to test 2,285 members of 743 families with at least three relatives with breast or ovarian cancer. Each of those families included at least one woman with breast cancer who had received normal results from complete commercial genetic testing for BRCA1 and BRCA2. The commercial tests were based on both Sanger sequencing and supplementary testing for large genomic rearrangements in both genes. Of the 743 families, 26% (191) were resolved by BROCA testing. The 191 resolved families were found to harbor 149 different inherited, damaging mutations in 18 distinct genes. Of the 191 resolved families, 35% (66) carried inherited, damaging mutations in BRCA1 or BRCA2 that were not detected by commercial sequencing. The scientists explained that the BRCA mutations were not detected by commercial testing for one of two reasons. In some families, the patient who was tested had normal sequences of BRCA1 and BRCA2, but her relatives with breast cancer carried a mutation in one of those genes. In other families, both the patient who was tested and her relatives carried a BRCA1 or BRCA2 mutation of a type not reported by commercial testing. In the remaining families resolved by BROCA, 65% (125) carried inherited, damaging mutations in genes other than BRCA1 or BRCA2 that also have been associated with breast cancer. The researchers found that 18 different genes harbored cancer-predisposing mutations in those 125 families, but each affected person carried a mutation in only one gene. Carriers of mutations in some of the genes were at significantly increased risk of ovarian cancer for women and increased risk of breast cancer in men as well as in women. Comprehensive testing is rapidly becoming more widespread. “It is important to determine more precisely the risks associated with damaging mutations in each of these genes so as to incorporate them most effectively into clinical care,” Dr. Walsh said. These assessments are best undertaken by sharing data across all centers that carry out genetic testing for breast and ovarian cancer risk, said Dr. King. In a post-presentation meeting with the press, Dr. King said that clinicians can send samples to her group at the University of Washington for BROCA panel testing. She expects that such panel testing will become increasingly available commercially, given the recent Supreme Court decision, and the costs will likely come down with the increased availability. Currently, the BROCA panel test ultimately costs the patient on the order of $3,800 after being requested by a clinician, although the University of Washington currently does its BROCA panel testing for free. BROCA panel testing has been done on approximately 6,000 research subjects and 500 patients so far, Dr. Walsh said. This BioQuick report is based largely on an ASHG press release. The ASHG is the primary professional membership organization for nearly 8,000 human genetics specialists worldwide. The ASHG Annual Meeting is the world's largest gathering of human genetics professionals and a forum for renowned experts in the field. Approximately 6,700 genetics professionals are attending the 2013 annual meeting in Boston, which runs through Saturday, October 26. For more information about the ASHG, visit: [ASHG press release] [U. Washington press release on Supreme Court gene patent ruling] [ASHG Annual Meeting 2013]